Matthew Gline - 30 Mar 2026 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Reporting relationship: CEO, Director
Issuer ticker: ROIV
Reported as of: 30 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2026, 19:20:32 UTC
Prior SEC filing: 17 Dec 2025
Next SEC filing: 20 Apr 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline

Key filing fact

Matthew Gline filed Form 4 for Roivant Sciences Ltd. (ROIV) on 01 Apr 2026.

Key facts

This page summarizes Matthew Gline's Form 4 filing for Roivant Sciences Ltd. (ROIV).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Apr 2026, 19:20.

Change

Previous filing in this sequence was filed on 17 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001750094 Primary reporting owner

Gline Matthew

Relationship: CEO, Director
Address: C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM
Signature: By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline
Signature date: 01 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Options Exercise

Transaction value
Shares: +97,319
Change %: +0.56%
Price
Shares after: 17,384,400
Date: 30 Mar 2026
Ownership: Direct
Footnotes: F1, F2

ROIV transaction

Common Shares

Tax liability

Transaction value
Shares: -53,826
Change %: -0.31%
Price: $26.41^*
Shares after: 17,330,574
Date: 30 Mar 2026
Ownership: Direct
Footnotes: F3

ROIV transaction

Common Shares

Tax liability

Transaction value
Shares: -304,684
Change %: -1.8%
Price: $27.70^*
Shares after: 17,025,890
Date: 31 Mar 2026
Ownership: Direct
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ROIV transaction Derivative

Capped Value Appreciation Rights

Options Exercise

Transaction value
Shares: -2,178,150
Change %: -100%
Price: $11.50^*
Shares after: 0
Date: 30 Mar 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 97,319
Exercise price
Footnotes: F1, F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount").

Footnote F2

On March 30, 2026, the hurdle price applicable to 2,178,150 vested CVARs was satisfied and, accordingly, the CVARs were settled into 97,319 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 30, 2026.

Footnote F3

Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such CVARs.

Footnote F4

Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

Footnote F5

Award of CVARs is fully vested.